United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2012_register executive 2012-05-15 article Notices D09002ee1c7fd05f9 D09002ee1c7fd0672 United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in PCT Patent Application No. PCT/US2009/054478, U.S. Patent Application No. 13/059,335 and foreign equivalents thereof entitled "Chemopreventive of Head and Neck Squamous Cell Carcinoma" (HHS Ref. No. E-302-2008/0) to Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd., which is located in Jerusalem, Israel. The patent rights in these inventions have been assigned to the United States of America. Other than license applications submitted as objections to this Notice of Intent to Grant an Exclusive License, no further license applications will be considered for the exclusive field of use set forth below if the Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. is granted an exclusive license pursuant to this Notice of Intent to Grant an Exclusive License. The prospective exclusive license territory may be worldwide and the field of use may be limited to use of the Licensed Patent Rights for the prevention and treatment of head and neck cancers. 77 FR 28614 https://www.govinfo.gov/app/details/FR-2012-05-15/2012-11690 2012-11690 fr15my12-78 4140-01-P https://www.govinfo.gov/app/details/FR-2012-05-15/2012-11690 https://www.govinfo.gov/content/pkg/FR-2012-05-15/html/2012-11690.htm https://www.govinfo.gov/content/pkg/FR-2012-05-15/pdf/2012-11690.pdf 1 p. 28614 28614 77 FR 28614 Prospective Grant of Exclusive License: Development of Chemopreventive Treatments for Head and Neck Squamous Cell Carcinoma; Federal Register Vol. 77, Issue NOTICE 2012-11690 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2012-06-14 4140-01-P 2012-11690 Notice.

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in PCT Patent Application No. PCT/US2009/054478, U.S. Patent Application No. 13/059,335 and foreign equivalents thereof entitled "Chemopreventive of Head and Neck Squamous Cell Carcinoma" (HHS Ref. No. E-302-2008/0) to Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd., which is located in Jerusalem, Israel. The patent rights in these inventions have been assigned to the United States of America. Other than license applications submitted as objections to this Notice of Intent to Grant an Exclusive License, no further license applications will be considered for the exclusive field of use set forth below if the Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. is granted an exclusive license pursuant to this Notice of Intent to Grant an Exclusive License. The prospective exclusive license territory may be worldwide and the field of use may be limited to use of the Licensed Patent Rights for the prevention and treatment of head and neck cancers.

Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 14, 2012 will be considered, in addition to the current non-exclusive applications under consideration, for the prospective license territory and field of use to be granted under the contemplated exclusive patent license. Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Whitney A. Hastings, Ph.D., Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 451-7337; Facsimile: (301) 402-0220; Email: hastingw@mail.nih.gov. Prospective Grants of Exclusive Licenses: Development of Chemopreventive Treatments for Head and Neck Squamous Cell Carcinoma , hastingw@mail.nih.gov Vol. 77, no. 94 Office of the Federal Register, National Archives and Records Administration 2012-05-15 continuing daily deposited born digital 294 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2012-05-15 P0b002ee1826a021f 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr15my12 https://www.govinfo.gov/app/details/FR-2012-05-15 https://www.govinfo.gov/content/pkg/FR-2012-05-15/pdf/FR-2012-05-15.pdf https://www.govinfo.gov/content/pkg/FR-2012-05-15/xml/FR-2012-05-15.xml fdlp 28471 28755 DGPO 2012-05-15 2024-06-03 FR-2012-05-15 machine generated eng FR FR-2012-05-15 77 94